Acute immune activation triggers adaptive sickness behaviour through the release of pro-inflammatory cytokines, such as interleukin-1 and -6 (IL-1 and -6), tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP). When the immune system is persistently activated, these disrupt normal feedback in the hypothalamic-pituitary-adrenal (HPA) axis (top left), leading to sustained cortisol release. Simultaneously, microglial cells in the brain shift from a resting to an activated state (top right). These disturbances contribute to a pro-inflammatory state that impairs brain regions involved in motivation, reward and cognition. Dysregulation of other pathways such as the tryptophan–kynurenine pathway (bottom right) further contributes to neurotransmitter imbalances, reducing serotonin availability and promoting neurotoxic metabolites.
Related content
Major Depressive Disorder (MDD) is a highly prevalent psychiatric condition with significant individual and socio-economic burden. Despite the broad availability of numerous effective therapeutic interventions, up to 30% of patients fail to achieve adequate symptom relief and are classified as having treatment-resistant depression (TRD). TRD represents a significant clinical challenge, affecting approximately 30% of individuals with MDD who fail to respond to at least two adequate antidepressant trials.
Sequential treatment optimization scheme for major depressive disorder generated according to international evidence.
Key steps for managing factors that may confound antidepressant treatment response, including dose, side effects, comorbidities, stressors, adherence, pharmacogenomics, interactions, and treatment algorithms.